Delivery Order SPE2DB24D1007-SPE2DB25FCCUL
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $46,854.75 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a $7,915.80 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Rexulti 1 mg tablets (30-count). This firm fixed-price, non-set-aside contract is scheduled for completion by July 28, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $2,927.61. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and represents a non-competitive set-aside award. The order will be performed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Rexulti 1 mg tablets (30-count units) with a ceiling value of $18,866.61. This non-set-aside contract award reflects a firm fixed price delivery order with an ultimate completion date of August 8, 2025. The contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $15,853.82. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,281.82 on July 29, 2025, for the supply of Rexulti 2 mg tablets in quantities of 30. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti is an atypical antipsychotic medication used in the...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCULDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,077.96 on August 8, 2025, for the supply of Rexulti 1 mg tablets (30-count packages). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 11, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle valued through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for medical procurement, particularly for Defense Health Agency and military healthcare systems. The company holds significant capacity to fulfill federal medical supply requirements through competitive award processes, as evidenced by its extensive portfolio of delivery orders across multiple therapeutic domains including specialty medications, vaccines, and medical devices. This specific delivery order for Rexulti, an atypical antipsychotic used in psychiatric treatment, represents routine pharmaceutical procurement under the company's established relationship with DLA to support military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 8/8/25 |